Cardiac lipid metabolism involves the coordination of sarcolemmal FA uptake, mitochondrial transport and beta-oxidation. These processes are under robust transcriptional control that is tightly coupled to substrate availability and metabolic demand. Genetic mutations in the genes that are critical regulators of cardiac lipid utilization often give rise to human cardiomyopathies. Therefore, a complete understanding of the transcriptional mechanisms which govern cardiac lipid metabolism is of critical importance. Studies in this proposal investigate a novel transcription factor termed KLF15 that modulates cardiac lipid utilization in vivo. KLF15 is a member of the Kruppel-like family of zinc-finger transcription factors and is known to regulate key aspects of cardiac hypertrophy, hepatic gluconeogenesis, and adipogenesis. However, a specific role for the KLF family in cardiac metabolism has not been reported. Preliminary results demonstrate that systemic deletion of Klf15 attenuates fatty acid oxidation in an isolated working heart preparation and is associated with reduced expression of multiple genes critical for myocardial lipid utilization. Interestingly, gain- and loss-of- function studies suggest KLF15 both regulates the expression of and cooperates with a member of the ligand activated nuclear receptor superfamily termed peroxisomal proliferator activated receptor-1 (PPAR1), a well established regulator of cardiac lipid metabolism. Consistent with these observations, PPAR1-dependent induction of canonical lipid metabolic gene targets is dependent on KLF15. Finally, cardiac restricted Klf15 deficient mice have been successfully generated. These observations underlie the central hypothesis of this application that KLF15 is a novel regulator of cardiac lipid metabolism. The goals of this proposal are: (1) To elucidate the precise molecular mechanism by which KLF15 regulates targets genes in the lipid utilization pathway;(2) To determine the effect of altering KLF15 levels, in a cardiac specific fashion, on lipid metabolism in vivo. These results will provide molecular, cellular, and whole-organ insights regarding the role of KLF15 as a modulator of cardiac lipid metabolism through a mechanism that involves, at least in part, cooperativity with PPAR1.
The heart has the capacity to utilize multiple substrates to meet its metabolic demand. However, pathologic states are often associated with a loss of this metabolic plasticity. The biochemical pathways which govern cardiac substrate metabolism are under robust molecular control. Given the worldwide epidemic of heart disease, a thorough understanding of the basic gene-regulatory mechanisms governing cardiac metabolism is of critical importance.
|Sun, Haipeng; Olson, Kristine C; Gao, Chen et al. (2016) Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 133:2038-49|
|Liao, Xudong; Zhang, Rongli; Lu, Yuan et al. (2015) Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J Clin Invest 125:3461-76|
|Prosdocimo, Domenick A; Anand, Priti; Liao, Xudong et al. (2014) Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem 289:5914-24|
|Lu, Yuan; Zhang, Lisheng; Liao, Xudong et al. (2013) Kruppel-like factor 15 is critical for vascular inflammation. J Clin Invest 123:4232-41|
|Jung, Dae Young; Chalasani, Umadevi; Pan, Ning et al. (2013) KLF15 is a molecular link between endoplasmic reticulum stress and insulin resistance. PLoS One 8:e77851|
|Haldar, Saptarsi M; Jeyaraj, Darwin; Anand, Priti et al. (2012) Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci U S A 109:6739-44|